论文部分内容阅读
目的探讨雷贝拉唑治疗幽门螺杆菌相关性胃溃疡的临床疗效。方法选取郑州大学附属洛阳中心医院2014年2月—2015年2月收治的78例幽门螺杆菌相关性胃溃疡患者,随机分为研究组和对照组,各39例。对照组采用奥美拉唑肠溶胶囊治疗,研究组采用雷贝拉唑钠肠溶片治疗,观察两组患者的临床疗效、幽门螺杆菌清除率、不良反应和复发情况。结果两组患者总有效率、不良反应发生率比较,差异无统计学意义(P>0.05)。研究组幽门螺杆菌清除率高于对照组,远期复发率低于对照组,差异有统计学意义(P<0.05)。结论雷贝拉唑治疗幽门螺杆菌相关性胃溃疡的临床疗效与奥美拉唑相当,不良反应少,且远期复发率较低。
Objective To investigate the clinical efficacy of rabeprazole in the treatment of Helicobacter pylori associated gastric ulcer. Methods 78 patients with Helicobacter pylori-associated gastric ulcer admitted to Luoyang Central Hospital of Zhengzhou University from February 2014 to February 2015 were randomly divided into study group and control group, with 39 cases in each group. The control group was treated with omeprazole enteric-coated capsules. The study group was treated with rabeprazole sodium enteric-coated tablets. The clinical efficacy, helicobacter pylori eradication rate, adverse reactions and recurrence were observed in both groups. Results The total effective rate and the incidence of adverse reactions in the two groups were not statistically different (P> 0.05). Helicobacter pylori eradication rate was higher in the study group than in the control group, the long-term recurrence rate was lower than the control group, the difference was statistically significant (P <0.05). Conclusion The clinical efficacy of rabeprazole in the treatment of Helicobacter pylori-associated gastric ulcer is comparable to that of omeprazole with less adverse reactions and lower long-term recurrence rate.